bluebird bio, Inc.

NasdaqGS:BLUE Stock Report

Market Cap: US$48.7m

This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

bluebird bio Management

Management criteria checks 3/4

bluebird bio's CEO is Andrew Obenshain, appointed in Nov 2021, has a tenure of 3.5 years. total yearly compensation is $1.83M, comprised of 39.9% salary and 60.1% bonuses, including company stock and options. directly owns 0.092% of the company’s shares, worth $44.86K. The average tenure of the management team and the board of directors is 3.3 years and 14.2 years respectively.

Key information

Andrew Obenshain

Chief executive officer

US$1.8m

Total compensation

CEO salary percentage39.94%
CEO tenure3.5yrs
CEO ownership0.09%
Management average tenure3.3yrs
Board average tenure14.2yrs

Recent management updates

Recent updates

High Noon For bluebird

May 25
User avatar

Patient Starts And Capacity Expansion Will Achieve Breakeven

Sustained patient demand and operational efficiency improvements are poised to enhance revenue growth and financial stability by driving cash flow breakeven.

Investors Don't See Light At End Of bluebird bio, Inc.'s (NASDAQ:BLUE) Tunnel And Push Stock Down 38%

Jan 04
Investors Don't See Light At End Of bluebird bio, Inc.'s (NASDAQ:BLUE) Tunnel And Push Stock Down 38%

bluebird bio, Inc.'s (NASDAQ:BLUE) Revenues Are Not Doing Enough For Some Investors

Nov 15
bluebird bio, Inc.'s (NASDAQ:BLUE) Revenues Are Not Doing Enough For Some Investors

bluebird bio: Scientific Success And Financial Success, And The Gap Between

Sep 26

bluebird bio's Flight Through Financial Fog And Fierce Rivals

Jun 27

bluebird bio Is Priced Below IP Value

Mar 23

Bluebird Bio: Innovative Therapies, Monetary Setbacks

Jan 25

Is bluebird bio (NASDAQ:BLUE) In A Good Position To Invest In Growth?

Oct 13
Is bluebird bio (NASDAQ:BLUE) In A Good Position To Invest In Growth?

Here's Why We're A Bit Worried About bluebird bio's (NASDAQ:BLUE) Cash Burn Situation

Jul 13
Here's Why We're A Bit Worried About bluebird bio's (NASDAQ:BLUE) Cash Burn Situation

Bluebird, Real Endpoints team up to increase access to pricey gene therapy Zynteglo

Oct 04

Bluebird bio names interim finance chief

Sep 26

Bluebird bio jumps 17% on FDA approval of new gene therapy

Sep 19

bluebird bio' chief strategy and financial officer to depart

Sep 12

CEO Compensation Analysis

How has Andrew Obenshain's remuneration changed compared to bluebird bio's earnings?
DateTotal CompensationSalaryCompany Earnings
Mar 31 2025n/an/a

-US$200m

Dec 31 2024US$2mUS$729k

-US$241m

Sep 30 2024n/an/a

-US$293m

Jun 30 2024n/an/a

-US$319m

Mar 31 2024n/an/a

-US$301m

Dec 31 2023US$3mUS$682k

-US$212m

Sep 30 2023n/an/a

-US$63m

Jun 30 2023n/an/a

-US$52m

Mar 31 2023n/an/a

-US$89m

Dec 31 2022US$2mUS$643k

-US$230m

Sep 30 2022n/an/a

-US$431m

Jun 30 2022n/an/a

-US$507m

Mar 31 2022n/an/a

-US$563m

Dec 31 2021US$9mUS$486k

-US$563m

Compensation vs Market: Andrew's total compensation ($USD1.83M) is above average for companies of similar size in the US market ($USD645.80K).

Compensation vs Earnings: Andrew's compensation has been consistent with company performance over the past year.

CEO

Andrew Obenshain (49 yo)

3.5yrs
Tenure
US$1,825,517
Compensation

Mr. Andrew Obenshain has been the President, Chief Executive Officer and Director of bluebird bio, Inc. since November 2021. He served as President of Severe Genetic Diseases since October 2020 until Novem...

Leadership Team

NamePositionTenureCompensationOwnership
Andrew Obenshain
President3.5yrsUS$1.83m0.092%
$ 44.9k
Thomas Klima
Chief Commercial & Operating Officer2.7yrsUS$850.72k0.035%
$ 17.0k
Joseph Vittiglio
Chief Legal & Business Officer and Secretary2.3yrsUS$897.29k0.012%
$ 5.7k
Oliver Sterling
CFO & Principal Accounting Officerless than a yearno datano data
Andrea Walton
Chief People Officer3.3yrsno datano data
Richard Colvin
Chief Medical Officer4.2yrsUS$1.34m0.028%
$ 13.7k
Scott Shoemaker
Senior Vice President of Technical Operations4.3yrsno datano data
3.3yrs
Average Tenure
52yo
Average Age

Experienced Management: BLUE's management team is considered experienced (3.3 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Andrew Obenshain
President3.5yrsUS$1.83m0.092%
$ 44.9k
Philip Reilly
Member of Scientific Advisory Board14.2yrsno datano data
Philippe Leboulch
Co-Chair of Scientific Advisory Boardno datano datano data
Stephen Goff
Member of Scientific Advisory Board14.2yrsno datano data
Mark Vachon
Independent Chairman10.8yrsUS$132.40k0.013%
$ 6.2k
Mitchell Finer
Member of Scientific Advisory Board9.8yrsUS$1.57mno data
Malcolm Brenner
Member of Scientific Advisory Board14.2yrsno datano data
Christof von Kalle
Member of Scientific Advisory Board14.2yrsno datano data
John Agwunobi
Independent Director7.9yrsUS$92.40k0.014%
$ 6.6k
Nick Leschly
Director15.2yrsUS$27.40k0.23%
$ 113.6k
R. Humphries
Member of Scientific Advisory Board14.2yrsno datano data
Elisabeth Leiderman
Independent Director3.5yrsUS$99.90k0.011%
$ 5.5k
14.2yrs
Average Tenure
65yo
Average Age

Experienced Board: BLUE's board of directors are seasoned and experienced ( 14.2 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/05/30 13:13
End of Day Share Price 2025/05/30 00:00
Earnings2025/03/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

bluebird bio, Inc. is covered by 21 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Zhiqiang ShuBerenberg
Matthew LuchiniBMO Capital Markets Equity Research
Dane LeoneBTIG